Name | GSK |
---|---|
Epic | GSK |
Isin | GB00BN7SWP63 |
Index | UK100 UK350 |
Industry | Pharmaceuticals & Biotechnology |
Latest share price | 1,337.00p | Net gearing | n/a |
---|---|---|---|
Market capitalisation | £55,419.98 | Debt ratio | n/a |
Shares in issue | 4,144.96 | Debt-to-equity ratio | n/a |
P/E ratio | 9.4 | Assets / equity ratio | n/a |
Total dividends per share | 58.00p | Price to book value | n/a |
Dividend yield | 2.9 | ROCE | 67.14 |
Dividend cover | 3.69 | EPS growth | 11 |
Earning per share | 121.6 | 52-week high / low | 1,300.00p / 1,812.50p |
Type | Ex-date | Pay-date | Net-dividend |
---|---|---|---|
Q4 | 2024-02-22 | 2024-04-11 | 16.00p |
Q3 | 2023-11-16 | 2024-01-11 | 14.00p |
Q2 | 2023-08-17 | 2023-10-12 | 14.00p |
Q1 | 2023-05-18 | 2023-07-13 | 14.00p |
Q4 | 2023-02-23 | 2023-04-13 | 13.75p |
Q3 | 2022-11-17 | 2023-01-12 | 13.75p |
Q2 | 2022-08-18 | 2022-10-06 | 16.25p |
Q1 | 2022-05-19 | 2022-07-01 | 14.00p |
Q4 | 2022-02-24 | 2022-04-07 | 23.00p |
Company name | GSK |
---|---|
Address | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS |
Telephone | +44 (0)20 8047 5000 |
Website | http://www.gsk.com |
Director | Position |
---|---|
Ms Emma Walmsley | CEO |
Mr Hal Barron | Non-Executive Director |
Dr Jeannie Lee | Non-Executive Director |
Mr Wendy Becker | Non-Executive Director |
Mr Jonathan Symonds | Non-Executive Chairman |
Mr Charles Bancroft | Senior Independent Non-Executive Director |
Ms Julie Brown | Chief Finance Officer |
Mr Harry (Hal) C. Dietz | Independent Non-Executive Director |
Mr Vishal Sikka | Independent Non-Executive Director |
Mr Elizabeth (Liz) McKee Anderson | Independent Non-Executive Director |
Dr Anne Beal | Independent Non-Executive Director |
Dr Jesse Goodman | Independent Non-Executive Director |
Assets £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
Intangible asssets and goodwill | 21579 | 21364 | 40631 |
Investments and other non-current assets | 1192 | 1541 | 2214 |
Total non-current assets | 40361 | 39377 | 60429 |
Inventory / work in progress | 5498 | 5146 | 5783 |
Trade and other receivables | 7385 | 7053 | 7860 |
Cash and equivalents | 2936 | 3723 | 4274 |
Other current assets and asset held for resale | 579 | 693 | 696 |
Total of all assets | 59005 | 60146 | 79103 |
Liabilities £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Short term liabilities | 21068 | 22810 | 23670 |
Long term liabilities | 25142 | 27240 | 34091 |
Other liabilites / pension etc | n/a | n/a | n/a |
Total of all liabilities | 46210 | 50050 | 57761 |
Net assets £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Net assets | 12795 | 10096 | 21342 |
Equity £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Share capital | 1348 | 1347 | 1347 |
Minority interests | -552 | -502 | 6287 |
Retained earnings | 7239 | 4363 | 7944 |
Share premium account | 3451 | 3440 | 3301 |
Total equity | 12795 | 10096 | 21342 |
Income £ (m) | 2023 | 2022 | 2021 |
---|---|---|---|
Turnover | n/a | n/a | n/a |
Operating profit | 6745 | 6433 | 4357 |
Pre-tax profit | 6064 | 5628 | 3599 |